Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 2Spondylitis, Ankylosing 1Signs and Symptoms 1Psoriasis 1Nutrition Disorders 1Lymphoma 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Inflammatory Bowel Diseases 1Glioma 1Gastroparesis 1Feeding and Eating Disorders 1Esophageal Neoplasms 1Epilepsy 1Dumping Syndrome 1Diarrhea 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 15pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Sulfasalazine × Clear all
NCT04205357 2023-03-03

SAS-GKRS

Haukeland University Hospital

Phase 1 Completed
24 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡